Sökning: onr:"swepub:oai:DiVA.org:umu-68682" >
Analysis of risk fa...
Analysis of risk factors in patients with severe chronic kidney disease. The role of atorvastatin.
-
- Holmberg, Benny, 1958- (författare)
- Umeå universitet,Medicin,Allmänmedicin
-
- Stegmayr, Bernd G, Professor (preses)
- Umeå universitet,Medicin
-
- Andersson, Christer (preses)
- Umeå universitet,Allmänmedicin
-
visa fler...
-
- Nilsson, Peter M, Professor (opponent)
- Institutionen för kliniska verksamheter, Lunds Universitet och klinisk forskningsenhet, Akutcentrum, Skånes universitetssjukhus, Malmö
-
visa färre...
-
(creator_code:org_t)
- ISBN 9789174595543
- Umeå : Umeå universitet, 2013
- Engelska 86 s.
-
Serie: Umeå University medical dissertations, 0346-6612 ; 1574
- Relaterad länk:
-
https://umu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background and aim: There had been no randomized end-point studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular end-points and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearanceMaterial & Methods: This was an open, prospective, randomized study. A total of 143 patients were included: 73 were controls and 70 were prescribed 10 mg/day of atorvastatin. As efficacy variables, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride levels were determined at the start of the study and at 1, 3, 6, 12, 18, 24, 30 and 36 months. The primary end-points were all cause of mortality, non-lethal acute myocardial infarction, and coronary artery intervention. Various risk factors were studied. In the 97 patients on haemodialysis inter dialysis weight gain (IDWG) was calculated as ultrafiltration in kg/body weight in kg given in percentage of the weight. The burden of IDWG was analyzed.Results: In the atorvastatin group, total cholesterol and low-density lipoprotein cholesterol were significantly reduced, the latter by 35% at 1 month and then sustained. Atorvastatin was withdrawn in 23% of patients due to unacceptable side effects, most frequent complaints being gastrointestinal discomfort and headache. Primary end-points occurred in 74% of the subjects. There was no difference in cardiovascular endpoint and survival between the control and atorvastatin groups. The 5-year end-point-free survival rate from study entry was 20%. There was no evidence of more benefit of atorvastatin for patients with diabetes mellitus and chronic kidney disease versus the other patients; instead plasma fibrinogen increased. The IDWG was significantly larger in patients who suffered from end-points due to cardiovascular reasons, cardiac reasons, congestive heart failure, aortic aneurysm, and intracerebral bleeding.Conclusion: These data showed that in contrast to other patient groups, patients with severe chronic kidney disease 4 and 5, including those with diabetes mellitus, seem to have no benefit from 10mg/day of atorvastatin. Instead we found a high IDWG to be an important risk factor that should be prevented. There was no evident connection between atorvastatin medication and IDWG.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Nyckelord
- Atorvastatin
- cholesterol
- chronic kidney disease
- haemodialysis
- cholesterol
- lipids
- peritoneal dialysis
- risk factors
- statins
- inter dialysis weight gain
Publikations- och innehållstyp
- vet (ämneskategori)
- dok (ämneskategori)
Hitta via bibliotek
Till lärosätets databas